Biomarker-guided antibiotic stewardship in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and process evaluation by Hellyer, T. P. et al.
              
City, University of London Institutional Repository
Citation: Hellyer, T. P., McAuley, D. F., Walsh, T. S., Anderson, N., Conway Morris, A., 
Singh, S., Dark, P., Roy, A. I., Perkins, G. D., McMullan, R., Emerson, L. M. ORCID: 0000-
0002-4250-5758, Blackwood, B., Wright, S. E., Kefala, K., O'Kane, C. M., Baudouin, S. V., 
Paterson, R. L., Rostron, A. J., Agus, A., Bannard-Smith, J., Robin, N. M., Welters, I. D., 
Bassford, C., Yates, B., Spencer, C., Laha, S. K., Hulme, J., Bonner, S., Linnett, V., Sonksen, 
J., Van Den Broeck, T., Boschman, G., Keenan, D. W. J., Scott, J., Allen, A. J., Phair, G., 
Parker, J., Bowett, S. A. and Simpson, A. J. (2019). Biomarker-guided antibiotic stewardship 
in suspected ventilator-associated pneumonia (VAPrapid2): a randomised controlled trial and 
process evaluation. The Lancet Respiratory Medicine, doi: 10.1016/s2213-2600(19)30367-4 
This is the published version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  http://openaccess.city.ac.uk/id/eprint/23310/
Link to published version: http://dx.doi.org/10.1016/s2213-2600(19)30367-4
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
www.thelancet.com/respiratory   Published online December 3, 2019   https://doi.org/10.1016/S2213-2600(19)30367-4 1
Articles
Lancet Respir Med 2019
Published Online 
December 3, 2019 
https://doi.org/10.1016/ 
S2213-2600(19)30367-4
See Online/Comment 
https://doi.org/10.1016/ 
S2213-2600(19)30406-0
Translational and Clinical 
Research Institute 
(T P Hellyer PhD, A J Rostron PhD, 
J Scott BSc, Prof A J Simpson PhD), 
National Institute for Health 
Research Newcastle In Vitro 
Diagnostics Cooperative 
(A J Allen PhD, Prof A J Simpson), 
and Newcastle Clinical Trials 
Unit (J Parker MClinRes, 
S A Bowett PhD), Newcastle 
University, Newcastle, UK; 
The Wellcome-Wolfson Centre 
for Experimental Medicine, 
Queen’s University Belfast, 
Belfast, UK 
(Prof D F McAuley MD, 
R McMullan MD, 
L M Emerson MPH, 
Prof B Blackwood PhD, 
Prof C M O’Kane PhD); 
Regional Intensive Care Unit 
(Prof D F McAuley) and 
Northern Ireland Clinical Trials 
Unit (A Agus PhD, G Phair MSc), 
The Royal Hospitals, Belfast, 
UK; Anaesthesia, Critical Care 
and Pain Medicine, University 
of Edinburgh, Queen’s Medical 
Research Institute, Edinburgh, 
UK (Prof T S Walsh MD); 
Intensive Care Unit, Royal 
Infirmary of Edinburgh, 
Edinburgh, UK (Prof T S Walsh, 
K Kefala MD); Usher Institute, 
University of Edinburgh, 
Edinburgh, UK 
(N Anderson PhD); Division of 
Anaesthesia, Department of 
Medicine, University of 
Cambridge, Addenbrooke’s 
Hospital, Cambridge, UK 
(A Conway Morris PhD); 
Department of Cancer and
Biomarker-guided antibiotic stewardship in suspected 
ventilator-associated pneumonia (VAPrapid2): a randomised 
controlled trial and process evaluation
Thomas P Hellyer, Daniel F McAuley, Timothy S Walsh, Niall Anderson, Andrew Conway Morris, Suveer Singh, Paul Dark, Alistair I Roy, 
Gavin D Perkins, Ronan McMullan, Lydia M Emerson, Bronagh Blackwood, Stephen E Wright, Kallirroi Kefala, Cecilia M O’Kane, 
Simon V Baudouin, Ross L Paterson, Anthony J Rostron, Ashley Agus, Jonathan Bannard-Smith, Nicole M Robin, Ingeborg D Welters, 
Christopher Bassford, Bryan Yates, Craig Spencer, Shondipon K Laha, Jonathan Hulme, Stephen Bonner, Vanessa Linnett, Julian Sonksen, 
Tina Van Den Broeck, Gert Boschman, DW James Keenan, Jonathan Scott, A Joy Allen, Glenn Phair, Jennie Parker, Susan A Bowett, 
A John Simpson
Summary
Background Ventilator-associated pneumonia is the most common intensive care unit (ICU)-acquired infection, yet 
accurate diagnosis remains difficult, leading to overuse of antibiotics. Low concentrations of IL-1β and IL-8 in 
bronchoalveolar lavage fluid have been validated as effective markers for exclusion of ventilator-associated pneumonia. 
The VAPrapid2 trial aimed to determine whether measurement of bronchoalveolar lavage fluid IL-1β and IL-8 could 
effectively and safely improve antibiotic stewardship in patients with clinically suspected ventilator-associated pneumonia.
Methods VAPrapid2 was a multicentre, randomised controlled trial in patients admitted to 24 ICUs from 17 National 
Health Service hospital trusts across England, Scotland, and Northern Ireland. Patients were screened for eligibility 
and included if they were 18 years or older, intubated and mechanically ventilated for at least 48 h, and had suspected 
ventilator-associated pneumonia. Patients were randomly assigned (1:1) to biomarker-guided recommendation on 
antibiotics (intervention group) or routine use of antibiotics (control group) using a web-based randomisation service 
hosted by Newcastle Clinical Trials Unit. Patients were randomised using randomly permuted blocks of size four and 
six and stratified by site, with allocation concealment. Clinicians were masked to patient assignment for an initial 
period until biomarker results were reported. Bronchoalveolar lavage was done in all patients, with concentrations of 
IL-1β and IL-8 rapidly determined in bronchoalveolar lavage fluid from patients randomised to the biomarker-based 
antibiotic recommendation group. If concentrations were below a previously validated cutoff, clinicians were advised 
that ventilator-associated pneumonia was unlikely and to consider discontinuing antibiotics. Patients in the routine 
use of antibiotics group received antibiotics according to usual practice at sites. Microbiology was done on 
bronchoalveolar lavage fluid from all patients and ventilator-associated pneumonia was confirmed by at least 
10⁴ colony forming units per mL of bronchoalveolar lavage fluid. The primary outcome was the distribution of 
antibiotic-free days in the 7 days following bronchoalveolar lavage. Data were analysed on an intention-to-treat basis, 
with an additional per-protocol analysis that excluded patients randomly assigned to the intervention group who 
defaulted to routine use of antibiotics because of failure to return an adequate biomarker result. An embedded 
process evaluation assessed factors influencing trial adoption, recruitment, and decision making. This study is 
registered with ISRCTN, ISRCTN65937227, and ClinicalTrials.gov, NCT01972425.
Findings Between Nov 6, 2013, and Sept 13, 2016, 360 patients were screened for inclusion in the study. 146 patients 
were ineligible, leaving 214 who were recruited to the study. Four patients were excluded before randomisation, 
meaning that 210 patients were randomly assigned to biomarker-guided recommendation on antibiotics (n=104) or 
routine use of antibiotics (n=106). One patient in the biomarker-guided recommendation group was withdrawn by 
the clinical team before bronchoscopy and so was excluded from the intention-to-treat analysis. We found no 
significant difference in the primary outcome of the distribution of antibiotic-free days in the 7 days following 
bronchoalveolar lavage in the intention-to-treat analysis (p=0·58). Bronchoalveolar lavage was associated with a 
small and transient increase in oxygen requirements. Established prescribing practices, reluctance for bronchoalveolar 
lavage, and dependence on a chain of trial-related procedures emerged as factors that impaired trial processes.
Interpretation Antibiotic use remains high in patients with suspected ventilator-associated pneumonia. Antibiotic 
stewardship was not improved by a rapid, highly sensitive rule-out test. Prescribing culture, rather than poor test 
performance, might explain this absence of effect.
Funding UK Department of Health and the Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
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Introduction
Ventilator-associated pneumonia is the most common 
infection acquired in intensive care units (ICUs),1 and is 
associated with substantial mortality, particu larly in 
the ageing ICU population.2 Broad-spectrum antibiotic 
use is recommended in suspected ventilator-associated 
pneumonia.3,4 However, diag nosis of this infection 
remains notoriously difficult, and pulmonary infection is 
typically confirmed in only 20–60% of sus pected cases.5 
Consequently, antibiotics are overused for suspected 
ventilator-associated pneumonia, potentially exposing 
patients to adverse effects, detracting from alternative 
causes of respiratory compromise, increasing costs, and 
driving emergence of antimicrobial resistance.5
Point prevalence studies suggest that 70% of patients 
in the ICU receive antibiotics.6 The association between 
increased antibiotic use and emergence of antimicrobial 
resistance in ICUs is well established.7 In the setting 
of hospital-acquired pneumonia, adherence to guide-
lines that promote broad-spectrum empirical antibiotics 
has been associated with adverse outcomes.8 This 
background has driven a need to rationalise antibiotic 
prescribing in ICUs.
Rapid diagnostic tests with the capacity to rule out 
ventilator-associated pneumonia might present early 
opportunities to optimise antibiotic prescription and 
decrease antibiotic use. Among protein-based biomarkers, 
only a combination of low IL-1β and IL-8 concentrations 
in bronchoalveolar lavage fluid has been validated in a 
multicentre setting in suspected ventilator-asso ciated 
pneumonia.9,10
The VAPrapid2 trial aimed to determine whether 
measurement of bronchoalveolar lavage fluid IL-1β and 
IL-8 could improve antibiotic stewardship without 
compromising patient safety in suspected ventilator-
associated pneumonia. In keeping with expert guidance 
on analysis of complex interventions,11 a process eva-
luation study was embedded in this trial.
Methods
Study design and participants
VAPrapid2 was a multicentre, randomised controlled 
trial in patients admitted to the ICU with suspected 
ventilator-associated pneumonia. The trial was done in 
24 ICUs from 17 National Health Service (NHS) hospital 
trusts across England, Scotland, and Northern Ireland.
Research in context
Evidence before this study
We searched Medline between Jan 1, 1996, and April 30, 2019, 
with the MeSH terms “Pneumonia”; “Pneumonia, bacterial”; 
“Pneumonia, Ventilator-Associated”; “Respiratory Tract 
Infections”; “Biomarkers”; “Protein Precursors”; and “Anti-
bacterial Agents”. Although several trials investigated the role 
of procalcitonin in reducing antibiotic use in lower respiratory 
tract infections, to our knowledge, few trials have been done in 
patients with ventilator-associated pneumonia. A multicentre 
trial of a procalcitonin-guided intervention to discontinue 
antibiotics in patients with ventilator-associated pneumonia 
reported a significant improvement in antibiotic-free days at 
28 days. However, the duration of antibiotics in both the 
intervention and the control groups of the trial were longer 
than the 8-day duration recommended in international 
guidelines. A further single-centre trial used a combination of 
the Clinical Pulmonary Infection Score and procalcitonin to 
guide antibiotic discontinuation in patients who had already 
completed 7 days of antibiotic therapy. Although patients in 
the procalcitonin group had more antibiotic-free days at 
28 days versus the control group, the duration of antibiotics in 
both groups was longer than 8 days. These studies focused on 
discontinuation of antibiotics once empirical treatment was 
established. To our knowledge, there are no published trials in 
which antibiotic stewardship is based on early exclusion of 
ventilator-associated pneumonia.
Added value of this study
To our knowledge, VAPrapid2 is the first trial to use a validated 
biomarker in a cohort of patients with clinically suspected 
ventilator-associated pneumonia, with an aim to determine 
whether early exclusion of ventilator-associated pneumonia 
could improve antibiotic stewardship. Furthermore, our trial 
included a process evaluation that aimed to understand clinical 
behaviours and implementation of the trial protocol. This trial 
showed that, although the biomarker test could accurately 
exclude ventilator-associated pneumonia, the trial 
recommendation regarding antibiotic discontinuation was 
seldom followed by clinicians, resulting in no difference in 
antibiotic use between the intervention and control groups. 
The results of this trial highlight entrenched behaviours in 
antibiotic prescribing practice and barriers to adopting new, 
unfamiliar technologies.
Implications of all the available evidence
Previous trials of procalcitonin have influenced the duration of 
antibiotic treatment in patients with ventilator-associated 
pneumonia. However, most patients with suspected ventilator-
associated pneumonia do not actually have it, subjecting them 
to unnecessary antibiotic treatment while the true cause of 
respiratory compromise potentially goes untreated. Avoiding 
antibiotic use in such patients remains an important goal for 
antibiotic stewardship in intensive care units. The VAPrapid2 
trial showed no influence on antibiotic prescribing practices in 
this patient group. Future studies should differentiate 
suspected from confirmed ventilator-associated pneumonia, 
aim to reduce antibiotics in patients who do not have 
confirmed infection, and dissect complex mechanisms that 
influence prescribing practices.
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Patients were screened for eligibility on weekdays and 
included if they were aged 18 years or older, intubated 
and mechanically ventilated for at least 48 h, and had 
suspected ventilator-associated pneumonia. Criteria for 
suspected ventilator-associated pneumonia were new or 
worsening chest radiographic (x-ray or chest CT) alveolar 
changes plus at least two of the following: body 
temperature less than 35°C or greater than 38°C, white 
cell count less than 4 × 10⁹/L or greater than 11 × 10⁹/L, 
and purulent tracheal secretions.5 Additionally, clinicians 
had to con sider eligible patients unlikely to have 
extrapulmonary infection requiring antibiotic treatment 
(ie, early discontinuation of antibiotics would be 
appropriate if ventilator-associated pneumonia was 
confidently excluded).
Patients were excluded if they fulfilled the criteria 
predicting poor tolerance of bronchoscopy and broncho-
alveolar lavage: PaO2 less than 8 kPa on FiO2 greater 
than 0·7, positive end-expiratory pressure greater than 
15 cmH2O, peak airway pressure greater than 35 cmH2O, 
heart rate greater than 140 beats per minute, mean 
arterial pressure less than 65 mm Hg, bleeding diathesis 
(platelet count <20 × 10⁹/L or international normalised 
ratio >3), intracranial pressure greater than 20 mm Hg, 
and ICU consultant considered bronchoscopy and 
bronchoalveolar lavage to be unsafe for the patient.
The research protocol was approved by the England and 
Northern Ireland (13/LO/065) and Scotland (13/SS/0074) 
National Research Ethics Service committees, and the trial 
protocol has been published previously.12 Patients or their 
relatives or representatives gave written informed consent 
for inclusion in the study.
Randomisation and masking
Patients were randomly assigned (1:1) to biomarker-
guided recommendation on antibiotics (intervention 
group) or routine use of antibiotics (control group) 
using a web-based randomisation service hosted by 
Newcastle Clinical Trials Unit (NCTU). Randomisation 
was triggered by the technician receiving each patient’s 
bronchoalveolar lavage fluid sample. The randomisation 
sequence was generated by the trial statistician using 
Sealed Envelope. Patients were randomised using 
randomly permuted blocks of size four and six and 
stratified by site, with allocation concealment. Participants 
underwent the same clinical procedures up to the point 
biomarker results were returned to the clinical service 
for the intervention group. Therefore, there was an initial 
period of double-blinding until test results were com-
municated to clini cians. As such, clinicians and research 
nurses were masked until the biomarker results became 
available.
Procedures
Investigators were asked to record a clinical opinion on 
the pre-test probability of ventilator-associated pneu-
monia in randomly assigned patients—high, medium, 
or low. A protocolised bronchoscopy and bronchoalveolar 
lavage was arranged for all randomly assigned patients 
using a 120 mL lavage with 0·9% saline.10 Samples were 
transported at 4°C to one of six testing laboratories 
(appendix p 5), with a transport time of up to 1·5 h.
IL-1β and IL-8 in bronchoalveolar lavage fluid were 
measured by cytometric bead array using Accuri C6 flow 
cytometers (Becton Dickinson Biosciences; San Jose, CA, 
USA). IL-1β and IL-8 concentrations in bronchoalveolar 
lavage fluid were entered into a previously derived 
equation for the exclusion of ventilator-associated pneu-
monia,10 and an automated calculation was made avail-
able to the laboratory staff processing bronchoalveolar 
lavage fluid samples. Instructions were communicated 
to clinicians by telephone immediately after results 
became available. For patients randomly assigned to 
the biomarker-guided group, the instruction relayed to 
clinicians was either, “Biomarker result above cutoff. 
Ventilator-associated pneumonia cannot be excluded, 
consider continuing antibiotics,” or “Biomarker result 
below cutoff. The negative predictive value is 1 and 
ventilator-associated pneumonia is very unlikely. 
Consider discontinuation of antibiotics.” For patients 
randomly assigned to routine use of antibiotics the 
instruction given to clinicians was, “Patient in routine 
use of anti biotics group.” If assays did not meet internal 
quality control criteria, clinicians were advised to default 
to routine care. The median negative predictive value 
previously calculated for the combination of IL-1β and 
IL-8 was 1·0 (95% CI 0·92–1·0).10
We defined confirmed ventilator-associated pneumonia 
as growth of a potentially pathogenic organism of at least 
10⁴ colony forming units (CFU) per mL of broncho-
alveolar lavage fluid.13 Microbiology testing was done in 
accredited NHS or Public Health England microbiology 
laboratories. Standard operating procedures for semi-
quan titative culture were done in accordance with the 
2012 UK Standards for Microbiology Investigation, 
issued by the Health Protection Agency. This strategy 
allowed samples to be quantified as having no growth, 
1–10 CFU/mL, 10–10² CFU/mL, 10²–10³ CFU/mL, 
10³–10⁴ CFU/mL, 10⁴–10⁵ CFU/mL, and so on, allowing 
simple and clear demarcation of bacteria grown at 
10⁴ CFU/mL or more (ventilator-associated pneumonia) 
and less than 10⁴ CFU/mL.
Investigators visited all ICUs before recruitment com-
menced, providing educational sessions on the diagnostic 
performance of the biomarkers and on the trial inter-
vention. Key components of trial design were reinforced 
through regular communication. Additional training was 
done in testing laboratories with respect to laboratory 
processes and biomarker measurement. Before the trial 
commenced, clinicians were again made aware of the 
biomarker test and were encouraged to follow the 
biomarker-guided recommendations. However, antibiotic 
use decisions were not mandated and were at clinicians’ 
discretion.
For more on Sealed Envelope 
see www.sealedenvelope.com
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A process evaluation was done with interviews of clinical 
staff and research staff (eg, site principal investigator, 
consultants, research nurses, and ward manager) in the 
following three phases: pre-trial (in month 1 of sites 
joining the trial; exploring routine diagnosis and 
management of ventilator-associated pneumonia), mid-
trial (once a site was involved in the trial for at least 1 year; 
exploring intervention quality, attitudes to the trial, and 
barriers or facilitators to suc cessful trial delivery), and late-
trial, with purposive sampling of nine sites based on pre-
trial and mid-trial results (in the final 3 months of the 
intervention period in June to Augsust, 2016; exploring 
local factors determining recruitment). Interviews were 
done by LME. Further details are in the appendix (p 4).
Outcomes
The primary outcome was the distribution of antibiotic-
free days in the 7 days following bronchoalveolar lavage. 
Antibiotic-free days were handled as an integer, with 
patients classified in one of eight categories (0–7 antibiotic-
free days, inclusive).
Predefined secondary outcomes were antibiotic-free 
days at days 14 and 28, antibiotic days at days 7, 14, and 
28, ventilator-free days at 28 days, 28-day mortality and 
ICU mortality, sequential organ failure assessment 
(SOFA) score at days 3, 7 and 14, duration of critical care 
(level 2 and level 3 care) and hospital stay, antibiotic-
associated infections (Clostridium difficile and meticillin-
resistant Staphylococcus aureus) up to hospital discharge, 
death, or 56 days, antibiotic-resistant pathogens (resistant 
to two or more antibiotics) cultured up to hospital dis-
charge, death, or 56 days, and health-care resource use 
calculated from length of critical care and hospital stay 
up to discharge, death, or 56 days. When considering 
outcomes at days 7, 14, and 28, antibiotics refers to all 
antibiotics given for treatment of infection; prophylactic 
antibiotics were not considered.
Since adverse clinical events are common in ICUs, the 
trial protocol mandated reporting of adverse events 
within 2 h of bronchoscopy. Clinical team members 
reported any further events after 2 h if they were con-
sidered clinically significant or related to the trial.
Statistical analysis
Full statistical methods were outlined in a Statistical 
Analysis Plan before the close of recruitment. Sample 
size was based on the change in frequency distribution 
of antibiotic-free days in the 7 days following broncho-
alveolar lavage. Models of change in distribution are 
outlined in the trial protocol.12 We deemed effect sizes 
in the region 0·07–0·08 to be of a clinically relevant 
magnitude. These effect sizes represent an approx -
imate change in median antibiotic-free days from 0 
(IQR 0·0–2·5) to 1·5 (0·0–3·5). There fore, we proposed 
a recruitment target of 90 patients per group, with an α 
of 0·05 and β of 0·20. Allowing for attrition of 14·3%, 
the target sample size was 210 patients. The primary 
analysis was done on the intention-to-treat population. 
We analysed the primary outcome by χ² test on a 
2 × 8 table of trial group versus antibiotic-free days. 
Sensitivity analyses were done using a discrete-time 
Cox proportional hazards model with centre and 
randomisation group as covariates, censored for death 
or end of follow-up at 7 days. We did a further sensitivity 
analysis, redefining antibiotic-free days as zero if 
death occurred within 7 days, as a more conservative 
approach.
We analysed secondary outcomes using Cox propor-
tional hazards models, logistic regression, linear regres-
sion, or Poisson regression as appropriate (see appendix 
p 4). Planned subgroup analyses included a per-protocol 
analysis, clinician assessment of likelihood of ventilator-
associated pneumonia, and admission category (medical, 
surgical caused by trauma or head injury, and other 
surgical). We excluded patients randomly assigned to the Figure: Trial profile
1 withdrawn by clinician
104 assigned to biomarker-guided recommendation 
on antibiotics (intervention group)
103 included in intention-to-treat analysis
81 included in per-protocol analysis
22 unsuccessful assays
106 assigned to routine use of antibiotics (control 
group)
106 included in intention-to-treat analysis
105 included in per-protocol analysis
1 withdrawn after randomisation
210 randomly assigned
214 recruited
360 patients screened
4 excluded
1 died before randomisation
2 clinicial withdrawal
1 no laboratory cover
146 excluded
29 not suitable for early discontinuation of antibiotics
14 PaO2 <8 kPa on FiO2 >0·7
1 positive end-expiratory pressure >15 cmH2O
1 heart rate >140 beats per min
3 bleeding diathesis
10 intracranial pressure >20 mm Hg
19 intensive care unit consultant deemed procedure to
not be safe in patient
3 declined consent
15 palliation
33 other
18 unknown
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intervention group who defaulted to routine use of 
antibiotics from the per-protocol analysis because they 
did not return a biomarker result.
We assessed the prevalence of missing data during a 
masked review after database lock, which was judged 
to be of sufficiently low frequency as to not require 
imputation for all variables. However, as prespecified in 
the Statistical Analysis Plan, SOFA scores were based on 
the last evaluable score. Unadjusted CIs and p values are 
reported for multiplicity.
The Newcastle upon Tyne Hospitals NHS Foundation 
Trust acted as sponsor for the trial. Clinical trial manage-
ment was provided by the NCTU. An independent 
data monitoring and safety committee oversaw the trial 
(appendix p 3).
Analyses were done with R version 3.3.2, with the 
addition of the discSurv package (version 1.3.4). This 
study is registered with ISRCTN, ISRCTN65937227, and 
ClinicalTrials.gov, NCT01972425.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between Nov 6, 2013, and Sept 13, 2016, 360 patients were 
screened for inclusion in the study. 146 patients were 
ineligible, leaving 214 who were recruited to the study. 
Four patients were excluded before randomisation, 
meaning that 210 patients were randomly assigned to 
biomarker-guided recommendation on antibiotics (n=104) 
or routine use of antibiotics (n=106; figure). One patient 
in the biomarker-guided recommendation group was 
withdrawn by the clinical team once baseline data were 
collected but before bronchoscopy, so was excluded from 
the intention-to-treat analysis.
Ventilator-associated pneumonia was confirmed in 
more patients in the intervention group than in the 
control group (table 1). The most commonly isolated 
pathogen in bronchoalveolar lavage fluid was S aureus 
(table 2). Clinician pre-test suspicion of ventilator-
associated pneumonia was high in most patients in the 
study (table 1). The biomarker assay had a negative 
likelihood ratio of 0·09 (95% CI 0·01–0·68; for more 
detail on test performance see appendix p 6). The mean 
time from broncho alveolar lavage to reporting results 
was 8 h and 10 min (SD 2 h 31 min).
We found no significant difference in the primary 
outcome of the distribution of antibiotic-free days in 
the 7 days following bronchoalveolar lavage, either in the 
intention-to-treat (p=0·58; table 3; appendix p 7) or per-
protocol analyses (p=0·28, table 3). In the biomarker-
guided group the IL-1β and IL-8 result was high in 
64 patients and low in 17 patients. In these 17 patients, the 
Biomarker-guided 
recommendation on 
antibiotics group (n=103)
Routine use of antibiotics 
group (n=106)
Age (years) 57·5 (16·1) 56·2 (15·9)
Sex
Female 37 (36%) 39 (37%)
Male 66 (64%) 67 (63%)
APACHE II score 18·6 (8·3) 16·6 (6·8)
Total SOFA score 5·2 (2·5) 4·9 (2·8)
SOFA respiratory 2·6 (0·9) 2·4 (1·0)
SOFA renal 0·4 (0·8) 0·5 (1·0)
SOFA hepatic 0·3 (0·6) 0·4 (0·8)
SOFA cardiovascular 1·6 (1·6) 1·3 (1·6)
SOFA haematological 0·3 (0·6) 0·4 (0·8)
Functional comorbidity index score 1·3 (1·4) 1·4 (1·2)
Medical admission 59 (57%) 70 (66%)
Surgical admission 44 (43%) 36 (34%)
Admission category
Respiratory 18 (17%) 24 (23%)
Gastrointestinal or liver 7 (7%) 10 (9%)
Cardiovascular 17 (17%) 9 (8%)
Trauma 23 (22%) 23 (22%)
Sepsis 4 (4%) 4 (4%)
Obstetrics and gynaecology 0 1 (1%)
Neurological (non-trauma) 20 (19%) 21 (20%)
Other 14 (14%) 14 (13%)
Clinician pre-test suspicion of ventilator-associated pneumonia*
Low 10 (10%) 7 (7%)
Medium 33 (32%) 51 (48%)
High 59 (57%) 48 (45%)
Number of days in ICU before bronchoalveolar 
lavage†
10·2 (8·7) 10·6 (10·4)
Confirmed ventilator-associated pneumonia‡ 38 (37%) 32 (30%)
Acute respiratory distress syndrome§
Mild (26·7–40·0 kPa) 11 (11%) 11 (10%)
Moderate (13·3–<26·7 kPa) 16 (16%) 11 (10%)
Severe (<13·3 kPa) 1 (1%) 5 (5%)
Vasopressors† 38 (37%) 37 (35%)
Renal replacement therapy 8 (8%) 4 (4%)
Use of corticosteroids 17 (17%) 15 (14%)
Receiving antibiotics at randomisation 83 (81%) 87 (82%)
Temperature (°C)* 37·4 (1·0) 37·7 (0·9)
White cell count (× 10⁹/L) 14·4 (5·4) 15·5 (7·2)
C-reactive protein (mg/L)¶ 153·0 (97·9) 157·6 (107·3)
Positive end-expiratory pressure (cm H2O)|| 7·5 (2·9) 7·8 (2·6)
Peak airway pressure (cm H2O)** 20·5 (6·4) 21·3 (7·1)
PaO2:FiO2 (kPa)†† 29·1 (20·4–39·7) 25·3 (18·5–36·0)
Data are mean (SD), n (%), or median (IQR). APACHE=acute physiology and chronic health evaluation. 
SOFA=sequential organ failure assessment. ICU=intensive care unit. *One patient from the biomarker-guided group 
missing. †Three patients (one from the biomarker-guided group) missing. ‡One patient from the routine use of 
antibiotics group missing. §Two patients (one from the biomarker-guided group) missing. ¶85 patients (43 from the 
biomarker-guided group) missing. ||Two patients from the biomarker-guided group missing. **23 patients (eight from 
the biomarker-guided group) missing. ††Seven patients (three from the biomarker-guided group) missing.
Table 1: Baseline characteristics
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recommendation to discontinue antibiotics was followed 
in four (24%) patients, and a false negative result was 
obtained in one (6%) patient. Microbiological details 
relating to bronchoalveolar lavage fluid from the 17 patients 
with a low IL-1β and IL-8 result (ie, those eligible for 
antibiotic discontinuation) are shown in the appendix (p 8).
We observed no significant differences between the 
groups for all other secondary outcomes (table 4). Results 
for subgroup analyses, per-protocol anal yses, and 
antibiotic-resistant infections are shown in the 
appendix (pp 10–17). Our two sensitivity analyses—one 
treating death as equivalent to zero antibiotic-free days 
and the other censoring at death in a discrete-time Cox 
model—revealed no difference in the primary outcome 
in the intention-to-treat population (appendix p 9).
Zero antibiotic-free days was the most frequent 
prescribing outcome (table 3). Median antibiotic days at 
day 7 were 6 (IQR 4–7) in both groups (hazard ratio [HR] 
0·84, 95% CI 0·63–1·12; table 4). We found no between-
group differences in antibiotic-free days at 14 days or 
28 days (table 4). Reported indications for antibiotics 
are described in the appendix (pp 18–19).
Numbers of patients with one or more reported adverse 
events or serious adverse events are shown in table 5. 
Details of adverse events and serious adverse events are 
shown in the appendix (p 20). Bronchoalveolar lavage 
was associated with a small, transient increase in oxygen 
requirements (appendix p 21).
In the 13 patients in whom the discontinuation 
recommendation was not followed, our process evalu-
ation suggested that perceived ventilator-associated 
pneu monia or hospital-acquired pneumonia was the 
most common reason for antibiotic use. The process 
evaluation identified two broad potentially negative 
influences on recruitment to the trial and compliance 
with the trial intervention. The first of these influences 
suggested that the chain involving identification of 
potential participants, preparation for bronchoalveolar 
lavage, laboratory processing, and a clinician making a 
judgement on the basis of the recommendation, intro-
duced many opportunities for deviation from the model. 
A breakdown in this sequence, at any stage, negatively 
affected site performance and implementation of the 
intervention. Second, we identified a pattern such that 
low recruitment by units appeared to correspond with 
less use of bronchoalveolar lavage in the diagnosis of 
ventilator-associated pneumonia outside the trial, a 
culture of not actively de-escalating antibiotics, and the 
absence of so-called trial champions (designated as 
having a particular interest in promoting and delivering 
the trial within a given unit). These same units also 
Ventilator-
associated 
pneumonia 
(≥10⁴ CFU/mL; 
n=70)
Non-ventilator-
associated 
pneumonia 
(<10⁴ CFU/mL; 
n=139)
Staphylococcus aureus 26 21*
Haemophilus spp 12 4
Escherichia coli 9 6
Pseudomonas aeruginosa 6 4
Klebsiella spp 5 15
Proteus mirabilis 5 3
Stenotrophomonas maltophilia 3 5
Streptococcus pneumoniae 3 1
Yeasts 3 13
Candida spp 2 17 
Citrobacter spp 2 2
Enterobacter spp 2 8
Serratia marcescens 2 3
Staphylococcus spp 2 6
Streptococcus spp 2 2
Acinetobacter spp 1 2
Anaerobes 1 0
Coliform 1 3
Corynebacterium spp 1 0
Enterococcus spp 1 1
Gram-positive cocci 1 2
Moraxella catarrhalis 1 0
Prevotella spp 1 0
Aspergillus fumigatus 0 4 
Burkholderia vietnamiensis 0 1
Morganella morganii 0 2 
Neisseria spp 0 1 
Data are n of isolates (in some bronchoalveolar lavage samples, more than one 
organism was isolated). 68 patients in the non-ventilator-associated pneumonia 
column had no growth. CFU=colony-forming units. *In one case the organism 
isolated was meticillin-resistant Staphylococcus aureus.
Table 2: Microorganisms isolated in bronchoalveolar lavage fluid
0 1 2 3 4 5 6 7
Intention-to-treat analysis
Biomarker-guided recommendation on antibiotics group (n=102) 50 (49%) 13 (13%) 7 (7%) 10 (10%) 7 (7%) 3 (3%) 4 (4%) 8 (8%)
Routine use of antibiotics group (n=105) 40 (38%) 14 (13%) 13 (12%) 18 (17%) 6 (6%) 4 (4%) 4 (4%) 6 (6%)
Per-protocol analysis
Biomarker-guided recommendation on antibiotics group (n=80) 42 (53%) 10 (13%) 7 (9%) 5 (6%) 6 (8%) 1 (1%) 3 (4%) 6 (8%)
Routine use of antibiotics group (n=105) 40 (38%) 14 (13%) 13 (12%) 18 (17%) 6 (6%) 4 (4%) 4 (4%) 6 (6%)
Data are n (%).
Table 3: Antibiotic-free days for the intention-to-treat and per-protocol analyses
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described a greater perception of risk for bronchoalveolar 
lavage (favouring less invasive methods) and for 
discontinuing antibiotics (favouring antibiotic use as the 
perceived lower-risk approach). For further details of the 
process evaluation see the appendix (pp 22–24).
Discussion
In the VAPrapid2 trial, a validated test with good rule-out 
characteristics for ventilator-associated pneumonia did 
not reduce antibiotic use or improve any of our other 
investigated clinical outcomes. To our knowledge, this is 
the first trial to use biomarkers to exclude ventilator-
associated pneumonia to increase confidence in early 
discontinuation of empirical antibiotics. Previous studies 
have shown proof of principle for modest antibiotic 
reduction in suspected ventilator-associated pneumonia 
using discontinuation rules.14,15 Serum procalcitonin has 
been studied widely in the ICU (outside the specific 
context of ventilator-associated pneumonia) and this 
approach showed varying success for safely adjusting 
antibiotic use.16–20 However, procalcitonin is ineffective for 
the exclusion of ventilator-associated pneumonia,21,22 
which was the focus of our approach. Inconsistent effects 
of procalcitonin on antibiotic use have also been des-
cribed for lower respiratory tract infection outside the 
ICU.23,24 Enthusiasm for a procalcitonin strategy in the 
ICU is offset by high non-compliance with procalcitonin 
guidance in general, and durations of procalcitonin-
guided antibiotic use in ventilator-associated pneumonia 
that exceed the widely accepted standard of 8 days.3,4,15,25 
Given that confirmation of ventilator-associated pneu-
monia is low in cases in which it is suspected,5 we 
reasoned that persuasive early evidence for the absence of 
ventilator-associated pneumonia might have a greater 
effect on antibiotic duration. Proof of concept for this 
general strategy had been provided by a single-centre 
study that used pre liminary microbiology culture results 
to stop antibiotics around 1 day after bronchoalveolar 
lavage.26
Biomarker-guided 
recommendation on 
antibiotics group (n=103)
Routine use of antibiotics 
group (n=106)
Effect size* (95% CI)
Antibiotic days (7 days post-bronchoalveolar lavage)† 6 (4–7) 6 (4–7) HR 0·84 (0·63 to 1·12)
Antibiotic days (14 days post-bronchoalveolar lavage)‡ 8 (6–12) 8 (5–11) HR 0·94 (0·69 to 1·28)
Antibiotic days (28 days post-bronchoalveolar lavage)§ 11 (7–15) 10 (5–15) HR 0·90 (0·65 to 1·25)
Antibiotic-free days (14 days post-bronchoalveolar lavage)‡ 6 (2–8) 6 (3–9) HR 1·13 (0·83 to 1·54)
Antibiotic-free days (28 days post-bronchoalveolar lavage)§ 17 (13–21) 18 (13–23) HR 1·01 (0·73 to 1·40)
Days of critical care stay¶ 14 (8–23) 14 (8–22) HR 1·00 (0·73 to 1·39)
Days of hospital stay|| 27 (16–58) 28 (12–50) HR 0·83 (0·60 to 1·15)
Days of level 3 (intensive care) stay¶ 10 (5–18) 10 (6–17) HR 1·05 (0·76 to 1·45)
Days of level 2 (high dependency) stay** 3 (1–8) 4 (1–7) HR 1·05 (0·74 to 1·48)
Mortality at 28 days†† 28 (27%) 21 (20%) OR 1·52 (0·78 to 2·98)
ICU mortality 25 (24%) 20 (19%) OR 1·35 (0·68 to 2·71)
Presence of antibiotic-associated infections to hospital 
discharge, death, or 56 days††
6 (6%) 7 (7%) OR 0·86 (0·26 to 2·71)
SOFA score at 3 days‡‡ 4·3 (2·6) 4·4 (2·7) –0·18 (–0·87 to 0·52)
SOFA score at 7 days§§ 4·0 (2·8) 4·1 (2·7) –0·13 (–0·85 to 0·59)
SOFA score at 14 days§§ 3·7 (2·8) 3·6 (3·0) 0·00 (–0·76 to 0·77)
Ventilator-free days (at 28 days) 11 (0–19) 9 (0–19) RR 1·03 (0·94 to 1·12)
Number of antibiotic-resistant pathogens to hospital 
discharge, death or 56 days††
0 (0–0) 0 (0–0) RR 1·71 (1·16 to 2·57)
Number of pathogens (outlier excluded) 0 (0–0) 0 (0–0) RR 1·36 (0·90 to 2·08)
Data are median (IQR), n (%), or mean (SD), unless otherwise indicated. The last row of the table excludes a single observation in the biomarker-guided group recorded as 
having multiple pathogens (more than twice any other patient). HR=hazard ratio. ICU=intensive car e unit. OR=odds ratio. SOFA=sequential organ failure assessment. 
RR=risk ratio. *Cox proportional hazards presented as HR, logistic regression presented as OR, linear regression presented as mean difference, and Poisson regression 
presented as RR. †Two patients (one from the biomarker-guided group) missing. ‡21 patients (11 from the biomarker-guided group) missing. §34 patients (14 from the 
biomarker-guided group) missing. ¶Six patients (three from the biomarker-guided group) missing. ||Five patients (two from the biomarker-guided group) missing. 
**61 patients (30 from the biomarker-guided group) missing. ††One patient from the biomarker-guided group missing. ‡‡12 patients (five from the biomarker-guided 
group) missing. §§Eight patients (three from the biomarker-guided group) missing.
Table 4: Secondary outcome measures
Biomarker-guided 
recommendation on 
antibiotics group (n=103)
Routine use of antibiotics 
group (n=106)
Adverse event or serious adverse event reported 43 (42%) 37 (35%)
Adverse event recorded 39 (91%) 35 (95%)
Serious adverse event recorded 4 (9%) 2 (5%)
Data are number of patients (%); multiple events were reported in some patients.
Table 5: Patients with reported adverse events or serious adverse events
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IL-1β and IL-8 fulfill the widely accepted criteria for a 
good exclusion test because they have a negative likeli-
hood ratio of less than 0·1.27 This second, independent 
validation of their performance in 24 ICUs under real-life 
conditions supports their diagnostic utility. This study 
yielded opportunities to discontinue antibiotics, but 
advice was only followed in four (24%) of 17 cases.
To our knowledge, this trial is among the first in critical 
care to embed a process evaluation, with the aim of 
understanding behaviours, in accordance with expert 
guidance.11 Our data suggest that the observed absence of 
effect was more likely to be explained by clinicians’ 
behaviour than by poor test performance. Before the trial 
commenced, the negative predictive value of the test was 
estimated at 1·0 (95% CI 0·92–1·00),10 therefore, the 
lower confidence limit could have affected clinicians’ 
confidence. However, the process evaluation did not 
provide evidence to sup port this theory. The process 
evaluation suggested that deeply entrenched prescribing 
characteristics probably underlie the lack of effect, as 
described in other settings.28,29 We attempted to mitigate 
non-compliance by including ICUs committed to the 
principle of accepting a recommenda tion to stop 
antibiotics. However, dissociation between intention and 
action in prescribing has been previously described.30–32
Inherent concern around failing to treat potential 
ventilator-associated pneumonia could have influenced 
prescribing, with fewer antibiotic-free days when pre-test 
probability was high. Beliefs around assumed efficacy 
and safety of antibiotics shape prescribing in emergency 
departments and presumably the motivation to avoid 
harm is enhanced in suspected ventilator-associated 
pneumonia in the ICU.28
In keeping with the broad spectrum of factors that 
determine successful introduction of complex diagnostic 
interventions,11,33 our process evaluation provided valuable 
and unexpected insights into influences that might 
affect delivery of a trial. The process evaluation suggested 
that recruitment often did not proceed because of identifi-
cation of restricted availability of broncho alveolar lavage or 
laboratory processing on the day, or because clinicians 
habitually preferred to complete anti biotic courses (thereby 
precluding enrolment). However, the main barrier to 
recruitment was clinician scepticism around the additional 
diagnostic value and safety of broncho alveolar lavage. The 
role of bronchoalveolar lavage in the diagnosis of ventilator-
associated pneu monia remains contentious.34,35 Broncho-
alveolar lavage is not a gold standard diagnostic for 
ventilator-associated pneumonia—simultaneous histo-
logical analysis and microbiological culture of alveolar 
tissue would give ideal diagnostic precision, but is neither 
practical nor ethical. We considered bronchoalveolar lavage 
the most pragmatic and accurate alternative, while 
recognising it to be an imperfect reference standard.5 
Considerable lack of familiarity with bronchoalveolar 
lavage in ICUs has been highlighted previously.36 The 
validation of test accuracy suggests that protocolised 
bronchoalveolar lavage was done to a high and uniform 
standard in this study. Furthermore, bronchoalveolar 
lavage was generally safe, although was associated with a 
small, transient increase in oxygen requirements, which 
has been noted elsewhere.37 Finally, the process evaluation 
strongly suggested that permanent research champions 
and ICU-trained research nurses devoted to the trial 
enhanced all aspects of recruitment and trial delivery. In 
units without research champions, attrition of recruit ment 
over time was pronounced and self-perpetuating.
There are several limitations to this study. There was a 
higher than expected number of assay failures early in 
the trial. Not all centres had the assay on site, although 
all had access within around 90 min of sample collection. 
The mean time taken to return test results from broncho-
alveolar lavage was more than 8 h. The study design left 
the decision to prescribe antibiotics with clinicians, rather 
than mandating stopping in accordance with test 
recommendations. Sites did not have a dedicated 
investigator who was responsible for recom mending 
discontinuation of antibiotics. We did not systematically 
collect data on sites’ pre-existing antibiotic stewardship 
policies or use of rapid diagnostics for infection, and we 
acknowledge the subjectivity of pre-test probability on the 
basis of clinician judgement. Although extrapulmonary 
infection was considered unlikely in eligible patients in 
our study, we cannot be certain that sources of infection 
outside the lung parenchyma (eg, pleural infection or 
subphrenic abscess) were absent. We did not collect cli-
nical pulmonary infection scores38 or ventilator-associated 
pneumonia severity scores,39,40 and we did not ascertain 
why patients who were taking corticosteroids had been 
prescribed these.
Whether fungi and various bacteria traditionally 
considered commensals can be considered a cause of 
ventilator-associated pneumonia when isolated from 
bronchoalveolar lavage at 10⁴ CFU/mL or more is con-
troversial.5 The argument that Candida is not a pathogen 
in ventilator-associated pneumonia has been strength-
ened by a recent prospective study,41 although the 
diagnosis of infection was partly based on endotracheal 
aspirate cultures. Our decision to consider the presence 
of such organisms at 10⁴ CFU/mL or more in broncho-
alveolar lavage fluid as ventilator-associated pneumonia 
was based on our previous studies and large clinical trials 
in suspected ventilator-associated pneumonia reporting 
substantial growth of these organisms.34,35 However, we 
acknowledge that many clinicians would not consider 
fungi, yeasts, or Enterococci as pathogens in ventilator-
associated pneumonia.
Controversy also surrounds the issue of whether 
patients with suspected ventilator-associated pneumonia 
should be included in trials if antibiotics have been 
started or adjusted in the 3 days before microbiological 
sampling, because of the theoretical risk of sterilising 
samples taken for culture.5 We elected to include such 
patients on the grounds that our derivation and validation 
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studies had similar ventilator-associated pneumonia 
rates (24% and 35%, respectively), with the derivation 
study excluding and the validation study including such 
patients. The similar ventilator-associated pneumonia 
rate in the current study (34%) provides evidence that 
inclusion of such patients did not materially alter 
ventilator-associated pneumonia rates. However, 
although there was only one false negative result iden-
tified for our test, it remains theoretically possible that 
bronchoalveolar lavage fluid samples might be sterile for 
technical reasons, such as inadequate sampling or delays 
in analysis, as has been described for blood cultures.42,43 
We attempted to mitigate this risk by implementing a 
protocolised bronchoalveolar lavage, ensuring timely 
delivery of samples and having quality control checks 
within the biomarker assay.
Finally, landmark studies of blood biomarkers of 
infection have taken advantage of changes in diagnostic 
parameters over serial timepoints.16,19,44 This study was 
confined to a single timepoint based on our previous data, 
the desire to provide results well before bronchoalveolar 
lavage fluid culture results were available to clinicians, 
and because the mild inflammation associated with 
bronchoalveolar lavage would confound results from 
subsequent lavages. However, we cannot be certain that 
we used the optimum timepoint(s) for sampling.
In conclusion, biomarker-guided exclusion of 
ventilator-associated pneumonia did not reduce antibiotic 
use in centres that had committed to following test 
recom mendations. Process evaluation suggested that 
lack of adoption of the technology and clinician behaviour 
had a greater influence on trial outcomes than did test 
performance. Antibiotic prescribing behaviours appear 
entrenched and recalcitrant to change. Future trials of 
diagnostic tests for ventilator-associated pneumonia 
should incorporate detailed implementation strategies 
informed by prior characterisation of factors that 
influence prescribing and diagnostic decision making.
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